invoX Pharma, a wholly-owned subsidiary of Sino Biopharmaceutical (HKEX: 1177) that is focused on research and development (R&D) and business development activities outside of China, today announced that it has entered into a definitive agreement to acquire all of the issued and outstanding shares of F-star Therapeutics’ (Nasdaq: FSTX) common stock for $7.12 per share.
The proposed acquisition values F-star, a UK and USA-based clinical-stage biopharmaceutical company, at approximately $161 million. The transaction has been unanimously approved by the invoX and F-star boards of directors and is expected to close in the second half of 2022.
News of the M&A deal pushed F-star’s shares up a massive 69% to $3.98 in pre-market trading this morning.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze